26 August 2021

The Corporate Finance team from independent UK law firm Burges Salmon has advised Edinburgh-headquartered dental technology company Calcivis Limited on a £1.52 million equity investment by Scottish Investment Bank, Archangels and others.

Calcivis has developed a biotechnology-based dental imaging system, which can identify active demineralisation tooth decay at an early stage, allowing dentists to use preventive treatments. The investment will assist with its ambitious growth plan to introduce the CALCiViS® Imaging System to the US market, with the aim of creating a new preventative dentistry segment in the US, which is anticipated to launch in Boston in 2022.

The Burges Salmon team advising Calcivis on the deal was led by partner Danny Lee and associate Katie Carter from the firm’s Corporate Finance team.

Katie comments: “We are pleased to have advised the Calcivis team on the successful completion of this latest fundraising. The deal marks an exciting new chapter in Calcivis’ journey, as it prepares for the launch of its dental imaging system in the US and we are proud to have played our part in helping their vision become a reality.”

Calcivis is an innovative UK dental biologic and device manufacturer focused on revolutionising treatment of tooth decay and enabling preventive dentistry. Headquartered in Edinburgh, Scotland, Calcivis brings world-class development and business management expertise to a sector eager to reduce reliance on costly, complex and painful surgical interventions. Calcivis is focused on revolutionising the management of dental demineralisation by providing what leading clinicians consider to be the “Holy Grail” of cariology (tooth decay): real-time chair side assessment of the caries disease process.

Key contact

Danny Lee

Danny Lee Partner

  • Mergers and Acquisitions
  • Private Equity
  • Joint Ventures

Subscribe to news and insight

Burges Salmon careers

We work hard to make sure Burges Salmon is a great place to work.
Find out more